Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US75886F1075
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000C734W3
REGN

Regeneron Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Regeneron Pharmaceuticals Inc
ISIN
US75886F1075
TICKER
REGN
MIC
XNAS
REUTERS
REGN.OQ
BLOOMBERG
REGN US
Tue, 23.12.2025       Regeneron Pharmaceuticals

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo...
Regeneron Pharmaceuticals
Mon, 22.12.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" pag...
Regeneron Pharmaceuticals
Sun, 07.12.2025       Regeneron Pharmaceuticals

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time...
Regeneron Pharmaceuticals
Tue, 25.11.2025       Regeneron Pharmaceuticals

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo...
Regeneron Pharmaceuticals
Wed, 19.11.2025       Regeneron Pharmaceuticals

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird ex Dividende/Zinsen gehandelt am 20.11.2025 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its ex-dividend/interest day on 20.11.2025...
Regeneron Pharmaceuticals
Wed, 19.11.2025       Regeneron Pharmaceuticals

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird ex Dividende/Zinsen gehandelt am 20.11.2025 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its ex-dividend/interest day on 20.11.2025...
Regeneron Pharmaceuticals
Wed, 19.11.2025       Regeneron Pharmaceuticals

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period...
Regeneron Pharmaceuticals
Thu, 13.11.2025       Regeneron Pharmaceuticals

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting...
Regeneron Pharmaceuticals
Sat, 08.11.2025       Regeneron Pharmaceuticals

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...
Regeneron Pharmaceuticals
Fri, 07.11.2025       Regeneron Pharmaceuticals

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared to placebo...
Regeneron Pharmaceuticals
Silent Ad
Mon, 03.11.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:...
Regeneron Pharmaceuticals
Fri, 31.10.2025       Regeneron Pharmaceuticals

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...
Regeneron Pharmaceuticals
Tue, 28.10.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update....
Regeneron Pharmaceuticals
Fri, 17.10.2025       Regeneron Pharmaceuticals

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p...
Regeneron Pharmaceuticals
Wed, 15.10.2025       Regeneron Pharmaceuticals

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-r...
Regeneron Pharmaceuticals
Sun, 12.10.2025       Regeneron Pharmaceuticals

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing...
Regeneron Pharmaceuticals
Wed, 08.10.2025       Regeneron Pharmaceuticals

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial ...
Regeneron Pharmaceuticals
Tue, 30.09.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time...
Regeneron Pharmaceuticals
Fri, 26.09.2025       Regeneron Pharmaceuticals

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH)...
Regeneron Pharmaceuticals
Mon, 22.09.2025       Regeneron Pharmaceuticals

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo...
Regeneron Pharmaceuticals
Silent Ad
Fri, 19.09.2025       Regeneron Pharmaceuticals

Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus...
Regeneron Pharmaceuticals
Wed, 17.09.2025       Regeneron Pharmaceuticals

Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss...
Regeneron Pharmaceuticals
Tue, 09.09.2025       Regeneron Pharmaceuticals

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone...
Regeneron Pharmaceuticals
Mon, 08.09.2025       Regeneron Pharmaceuticals

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...
Regeneron Pharmaceuticals
Thu, 04.09.2025       Regeneron Pharmaceuticals

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y...
Regeneron Pharmaceuticals
Thu, 04.09.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025....
Regeneron Pharmaceuticals
Tue, 26.08.2025       Regeneron Pharmaceuticals

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score...
Regeneron Pharmaceuticals
Wed, 20.08.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Co...
Regeneron Pharmaceuticals
Thu, 14.08.2025       Regeneron Pharmaceuticals

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 15.08.2025 und ex Dividende/Zinsen am 18.08.2025 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 15.08.2025 and its ex-dividend/interest day on 18.08.2025...
Regeneron Pharmaceuticals
Fri, 01.08.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update....
Regeneron Pharmaceuticals
Wed, 02.07.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prio...
Regeneron Pharmaceuticals
Thu, 26.06.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time th...
Regeneron Pharmaceuticals
Fri, 20.06.2025       Regeneron Pharmaceuticals

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP...
Regeneron Pharmaceuticals
Sun, 15.06.2025       Regeneron Pharmaceuticals

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints...
Regeneron Pharmaceuticals
Sat, 07.06.2025       Regeneron Pharmaceuticals

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color...
Regeneron Pharmaceuticals
Mon, 02.06.2025       Regeneron Pharmaceuticals

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China...
Regeneron Pharmaceuticals
Sat, 31.05.2025       Regeneron Pharmaceuticals

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)...
Regeneron Pharmaceuticals
Fri, 30.05.2025       Regeneron Pharmaceuticals

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit...
Regeneron Pharmaceuticals
Thu, 22.05.2025       Regeneron Pharmaceuticals

First results to be presented in two ASCO oral presentations...
Regeneron Pharmaceuticals
Mon, 19.05.2025       Regeneron Pharmaceuticals

Purchase is subject to bankruptcy court and regulatory approvals...
Regeneron Pharmaceuticals
Fri, 16.05.2025       Regeneron Pharmaceuticals

Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world’s largest pre-college STEM competition in Columbus, Ohio...
Regeneron Pharmaceuticals
Thu, 15.05.2025       Regeneron Pharmaceuticals

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market...
Regeneron Pharmaceuticals
Thu, 01.05.2025       Regeneron Pharmaceuticals

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma...
Regeneron Pharmaceuticals
Tue, 29.04.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update....
Regeneron Pharmaceuticals
Mon, 28.04.2025       Regeneron Pharmaceuticals

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma...
Regeneron Pharmaceuticals
Mon, 28.04.2025       Regeneron Pharmaceuticals

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice...
Regeneron Pharmaceuticals
Tue, 22.04.2025       Regeneron Pharmaceuticals

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region...
Regeneron Pharmaceuticals
Fri, 18.04.2025       Regeneron Pharmaceuticals

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYL...
Regeneron Pharmaceuticals
Fri, 18.04.2025       Regeneron Pharmaceuticals

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo...
Regeneron Pharmaceuticals
Thu, 17.04.2025       Regeneron Pharmaceuticals

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies...
Regeneron Pharmaceuticals